The BILAG-2004 index is sensitive to change for assessment of SLE disease activity

Rheumatology (Oxford). 2009 Jun;48(6):691-5. doi: 10.1093/rheumatology/kep064. Epub 2009 Apr 24.

Abstract

Objective: To determine if the BILAG-2004 index is sensitive to change for assessment of SLE disease activity.

Methods: This was a prospective multi-centre longitudinal study of SLE patients. At every assessment, data were collected on disease activity (BILAG-2004 index) and treatment. Analyses were performed using overall BILAG-2004 index score (as determined by the highest score achieved by any of the individual systems) and all the systems scores. Sensitivity to change was assessed by determining the relationship between change in disease activity and change in therapy between two consecutive visits. Statistical analyses were performed using multinomial logistic regression.

Results: There were 1761 assessments from 347 SLE patients that contributed 1414 observations for analysis. An increase in therapy between visits occurred in 22.7% observations, while 37.3% had a decrease in therapy and in 40.0% therapy was unchanged. Increase in overall BILAG-2004 index score was associated with increase in therapy and inversely associated with decrease in therapy. Decrease in overall BILAG-2004 index score was associated with decrease in therapy and was inversely associated with increase in therapy. Changes in overall BILAG-2004 index score were differentially related to change in therapy, with greater change in score having greater predictive power. Increase in the scores of most systems was independently associated with an increase in treatment and there was no significant association between decreases in the score of any system with an increase in therapy.

Conclusions: The BILAG-2004 index is sensitive to change and is suitable for use in longitudinal studies of SLE.

Publication types

  • Multicenter Study
  • Research Support, Non-U.S. Gov't
  • Validation Study

MeSH terms

  • Adult
  • Disease Progression
  • Female
  • Follow-Up Studies
  • Humans
  • Immunosuppressive Agents / therapeutic use
  • Logistic Models
  • Lupus Erythematosus, Systemic / drug therapy
  • Lupus Erythematosus, Systemic / immunology*
  • Lupus Nephritis / drug therapy
  • Lupus Nephritis / immunology
  • Male
  • Middle Aged
  • Prospective Studies
  • Sensitivity and Specificity
  • Severity of Illness Index*
  • Treatment Outcome

Substances

  • Immunosuppressive Agents